Has Belagodu Kantharaj received payments from drug or device companies?

Yes. Drug and device makers reported $7,946 in general payments to Belagodu Kantharaj across 186 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Belagodu Kantharaj did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Belagodu Kantharaj come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Belagodu Kantharaj

Hematology & Oncology · Elyria, OHNPI 1982656005

Payments from drug & device makers

What this record shows

The money is spread across several categories — food and beverage (55.2%), consulting fees and education — rather than concentrated in one kind of arrangement. 50 manufacturers reported payments, led by Jazz Pharmaceuticals Inc. at 41.4% of the total. Reporting peaked in 2022 at $3,853 and has fallen 87.5% since, to $482 in 2023.

$7,946in general payments, 2019–2025

Across 186 payments — averaging $42.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Jazz Pharmaceuticals Inc.$3K
Incyte Corporation$805
E.r. Squibb & Sons, L.L.C.$387
AstraZeneca$359
Seagen Inc.$313
Sirtex Medical Inc$254
plus $3K from 44 others

What the payments were for

Consulting fees$3,15040%
Food & beverage$4,38455%
Education$4135%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Jazz Pharmaceuticals Inc.	3	$3,291
Incyte Corporation	12	$805
E.r. Squibb & Sons, L.L.C.	18	$387
AstraZeneca(2 entities)	14	$359
Seagen Inc.	8	$313
Sirtex Medical Inc	1	$254
Astellas Pharma US Inc	7	$226
Lilly USA, LLC	8	$213
Novartis	9	$157
Eisai Inc.	8	$141
Takeda Pharmaceuticals U.S.A., Inc.	4	$137
Bayer	7	$127
Pfizer	7	$115
Bristol Myers Squibb	7	$105
Sanofi	5	$105
Merck	6	$99
Amgen	5	$94
Johnson & Johnson(2 entities)	5	$76
EMD Serono, Inc.	4	$73
Pharmacyclics LLC, An Abbvie Company	4	$66
Genentech USA, Inc.	4	$62
ASD Specialty Healthcare, LLC	1	$61
Beigene USA, Inc.	1	$50
Teva Pharmaceuticals USA, Inc.	1	$50
Heron Therapeutics, Inc.	3	$47
Blueprint Medicines Corporation	2	$44
Daiichi Sankyo Inc.	2	$31
Coherus Oncology, Inc.	1	$27
Exelixis Inc.	2	$26
Puma Biotechnology, Inc.	2	$26
Boehringer Ingelheim	2	$25
Medtronic	2	$25
Regeneron Healthcare Solutions, Inc.	1	$24
Gilead	2	$24
Kyowa Kirin, Inc.	2	$23
Clovis Oncology, Inc.	2	$22
Genmab U.S., Inc.	1	$21
Secura Bio, Inc.	1	$21
Helsinn Therapeutics (U.S.), Inc.	1	$20
AbbVie	1	$20
Progenics Pharmaceuticals, Inc.	1	$20
CSL Behring	1	$19
Morphosys, US Inc.	1	$17
Advanced Accelerator Applications	1	$15
Verastem, Inc.	1	$15
Karyopharm Therapeutics Inc.	1	$15
ADC Therapeutics America, Inc.	1	$14
Mylan Institutional Inc.	1	$14
Rigel Pharmaceuticals, Inc.	1	$12
Lexicon Pharmaceuticals, Inc.	1	$12

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,946 in reported general payments places this provider in the 65th percentile of 450 hematology & oncology providers in Ohio.

See all hematology & oncology providers in Ohio →

Other hematology & oncology in Elyria

Hillard LazarusCleveland$2M
Kasra KaramlouSandusky$1.8M
David WaterhouseCincinnati$1.3M
Taral PatelColumbus$888K
Tarek ChidiacColumbus$765K
Saulius GirniusMontgomery$707K
Ronald BukowskiCleveland$594K
Balazs HalmosCleveland$568K
Jorge GarciaCleveland$513K
Alejandro CalvoKettering$463K

See the full list for Ohio →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →